Stock Market Update - March 23, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. UGRO - urban-gro, Inc.
Price: $6.15 | Change: +182.11% ($3.97)
UGRO experienced an eye-popping 182.11% gain in its stock price around March 24, 2026. This massive surge was primarily driven by the completion of urban-gro, Inc.'s strategic all-stock merger with Flash Sports & Media Inc. This merger brought a substantial portfolio of T20 cricket league commercial rights, including the Lanka Premier League (LPL), onto urban-gro's Nasdaq-listed platform.
Following the merger, the combined entity announced aggressive expansion plans into high-growth cricket markets such as Bangladesh and the United Arab Emirates. This strategic move aims to consolidate multiple emerging-market cricket leagues under a single, capital-backed, and publicly governed structure designed to foster long-term growth and scalability, with a focus on developing recurring revenue streams.
What makes this particularly interesting is the creation of a centralized, transparent platform for various global cricket leagues, aiming for professional management and stable financial growth. This positive news was further bolstered by urban-gro having recently regained full Nasdaq compliance, adding to overall market confidence.
2. MGRX - Mangoceuticals, Inc.
Price: $0.3237 | Change: +99.81% ($0.1617)
MGRX just saw an impressive 99.81% gain, primarily around March 24, 2026. This significant movement was largely driven by two key company announcements.
A major catalyst appears to be the civil lawsuit filed by Mangoceuticals against its former technology firm, Clarity Ventures. The company is seeking over $73 million, alleging Clarity failed to deliver a functional e-commerce platform. Importantly, Mangoceuticals has since developed and deployed its own proprietary telehealth and e-commerce platform, which seems to have reassured investors by demonstrating resilience and self-sufficiency.
Adding to the positive sentiment was the international patent application for their MGX-0024 antiviral technology. This filing aims to secure global protection for technology designed to inhibit virus infection in animals, following impressive field trials that reported zero respiratory-related mortality in 29,000 birds and prophylactic benefits against H5N1. This dual catalyst—addressing a significant operational challenge while also demonstrating innovative progress in animal health—appears to have fueled investor excitement.
3. PTLE - PTL Limited
Price: $8.01 | Change: +87.59% ($3.74)
PTLE:NASDAQ saw an impressive 87.59% gain, largely fueled by two significant positive developments for the company. Most crucially, PTL Limited successfully regained compliance with Nasdaq's minimum bid price requirement. This meant their stock price stayed above $1.00 for a required period, effectively removing the immediate risk of delisting that had been a concern since last year. A share consolidation, or reverse stock split, was a key step in helping them achieve this.
Additionally, PTL Limited announced the acquisition of Twocap Limited, a Hong Kong-based company, which strategically expands their business into the regulated money lending market. This move allows them to offer new financing services, complementing their existing marine fuel logistics operations. The market's strong reaction around March 24th appears to be a delayed but enthusiastic response to these developments, indicating renewed investor confidence after the company addressed its delisting concerns and broadened its business scope.
4. BIAF - bioAffinity Technologies, Inc.
Price: $4.73 | Change: +73.26% ($2)
BIAF:NASDAQ recently surged with an impressive 73.26% gain, driven by exciting developments around its lung cancer diagnostic, CyPath® Lung. The company reported record-breaking 2025 revenue and unit sales for the product, with testing revenue jumping 87% and unit volume soaring 99% year-over-year. This strong financial performance was accompanied by a forecast of over 100% unit sales growth for CyPath® Lung in 2026, signaling continued expansion.
Further fueling investor confidence, BioAffinity Technologies initiated a large-scale, 2,000-patient clinical study for CyPath® Lung, aimed at evaluating its use for early lung cancer detection in high-risk individuals. A new case study also highlighted the test’s ability to provide actionable results and help patients avoid invasive procedures, collectively leading to a "sharp sentiment reset" for the stock.
What makes this particularly interesting is CyPath® Lung's potential to significantly impact lung cancer detection. Its focus on non-invasive early identification and its ability to help patients avoid invasive procedures, backed by a major clinical study, positions it as a key player in improving patient outcomes in a critical health area.
5. JZ - Jianzhi Education Technology Group Company Limited
Price: $1.71 | Change: +52.68% ($0.59)
JZ recently surged by an impressive 52.68%. This significant upward movement was primarily ignited by an announcement from Jianzhi Education Technology Group about an upcoming Extraordinary General Meeting (EGM).
At this meeting, scheduled for April 20, 2026, shareholders will vote on a proposal to drastically increase the company's authorized share capital. Essentially, Jianzhi is looking to expand the total number of shares it's legally permitted to issue, from around 10 billion to a massive 1 trillion.
Such a monumental expansion often signals that a company might be preparing for major strategic initiatives. This could include raising substantial capital for future growth, funding potential acquisitions, or making significant new investments, which likely fueled market speculation and drove investor interest.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.